12 WORLD GASTROENTEROLOGY NEWS JANUARY 2016 Gastro 2015: AGW-WGO | Expert Point of View | Gastro 2016: EGHS-WGO | WDHD News | WGO & WGOF News | WGO Global Guidelines | Calendar of Events 6. Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, et al. Controversies in the diagnosis and management of NAFLD and NASH. Gastroenterol Hepatol (N Y). 2014;10:219-227. 7. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second lead-ing etiology of liver disease among adults awaiting liver transplanta-tion in the United States. Gastro-enterology. 2015;148:547-555. 8. Zezos P, Renner EL. Liver trans-plantation and non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15532–15538. 9. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. 10. Milic S, Mikolasevic I, Krznaric- Zrnic I, Stanic M, Poropat G, Stimac D, et al. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther. 2015;9:4835-4845. 11. McPherson S, Hardy T, Hender-son E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD pro-gression from steatosis to fibros-ing- steatohepatitis using paired biopsies: implications for prog-nosis and clinical management. J Hepatol. 2015;62:1148-1155. 12. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and manage-ment of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, Ameri-can College of Gastroenterology, and the American Gastroentero-logical Association. Hepatology. 2012;55:2005-2023. 13. Sasso M, Audière S, Kemgang A, Gaouar F, Corpechot C, Chazouil-lères O,et al. Liver steatosis as-sessed by Controlled Attenuation Parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnos-tic accuracy. Ultrasound Med Biol. 2015 Sep 16. pii: S0301- 5629(15)00490-1. 14. de Lédinghen V, Vergniol J, Cap-depont M, Chermak F, Hiriart JB, Cassinotto C, et al. Controlled at-tenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60:1026-1031. 15. Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenua-tion parameter and liver stiffness measurements: a prospective cohort study. Gut. 2015 Apr 14. pii: gutjnl-2015-309265. doi: 10.1136/gutjnl-2015-309265. Epub ahead of print. NOW ONLINE - E-WGN EXPERT POINT OF VIEW ARTICLES COLLECTION! Did you enjoy this expert point of view article? We invite you to check out the entire collection of Scientific and Ex-pert Point of View articles from e-WGN from the past five years on the new WGO website. You can view this article and more at www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection.
ewgn-vol20-issue4-FINAL
To see the actual publication please follow the link above